This clinical trial focuses on testing lozenges containing benzydamine hydrochloride and 2,4-dichlorobenzyl alcohol for treating acute pharyngitis, which is a condition causing throat inflammation and soreness. The study aims to determine if these lozenges are effective in providing symptom relief for people with acute throat inflammation.

The study will compare three different treatments: DoriDuo lozenges (containing both active ingredients), Mebocaína Anti-Inflam lozenges (containing the same active ingredients), and a placebo. The medications will be given as throat lozenges that dissolve in the mouth. The maximum daily dose will be 25.2 mg, and the treatment will last up to 4 weeks.

During the study, participants will take the assigned lozenges and have their throat soreness levels monitored, particularly in the first two hours after taking the medication. The study is designed to show whether the new medication works better than the placebo and is at least as effective as the existing treatment. All medications will be given in a way that neither the patients nor the doctors know which treatment is being used.